mRNAbased cancer vaccine in patients with MGMT unmethylated glioblastoma (GBM): first results from the dose escalation phase

This study presents the findings of the first-in-human investigation of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed, surgically resected, and MGMT-unmethylated glioblastoma, (GBM), a group historically characterized by poor prognosis and limited treatment options (1).